Medical innovation is reshaping how disease is detected, treated, and even altogether prevented. Advances such as AI-supported diagnostics, genetic profiling and gene and cell therapies are transforming clinical practice and influencing multiple dimensions of risk management.
These developments have significant implications for insurers – from biometric risk assessment and product design to their evolving role in supporting better health outcomes.
Drawing on findings from our new report, Insuring Tomorrow’s Cures, this webinar explored how insurers are preparing for potential shifts in mortality, morbidity, and longevity trends. We examined emerging financing models as breakthrough therapies reach the market, and considered how insurers can contribute to sustainable, value-driven healthcare ecosystems.
Finally, we discussed how pharmaceutical manufacturers are approaching market access, pricing, and partnership models in an environment where healthcare spending is increasingly aligned with measurable clinical and economic value.
